Results 141 to 150 of about 453,251 (315)

Successful treatment of recalcitrant follicular lichen planus (lichen planopilaris) with the topical JAK 1/2 inhibitor ruxolitinib

JEADV Clinical Practice
We report the successful treatment of a patient with refractory follicular lichen planus (LP) with topical ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor, which resulted in significant improvement of lesional skin within 1 month of daily use.
Tanja Fetter, Dagmar Wilsmann‐Theis, Luka deVos‐Hillebrand, Natalija Novak, Joerg Wenzel   +4 more
doaj   +1 more source

Gut microbiome‐derived metabolites show promise in cancer research and therapy

Interdisciplinary Medicine, EarlyView.
The metabolites produced by the gut microbiome, which are subject to regulation by multiple factors, play a pivotal role in the progression of various types of cancer. These metabolites not only function as potential biomarkers for the early detection and monitoring of tumor development, but also actively participate in cancer therapeutic processes ...
Kangjie Yang, Yifan Wang, Daolin Tang, Peilong Li, Lutao Du   +4 more
wiley   +1 more source

Leptin induces upregulation of sphingosine kinase 1 in oestrogen receptor-negative breast cancer via Src family kinase-mediated, janus kinase 2-independent pathway

Breast Cancer Research, 2014
IntroductionObesity is a known risk factor for breast cancer. Sphingosine kinase 1 (SK1) is an oncogenic lipid kinase that is overexpressed in breast tumours and linked with poor prognosis, however, its role in obesity-driven breast cancer was never ...
H. Alshaker, J. Krell, A. Frampton, J. Waxman, O. Blyuss, A. Zaikin, M. Winkler, J. Stebbing, E. Yagüe, D. Pchejetski   +9 more
semanticscholar   +1 more source

Multicenter experience using tofacitinib for treatment of refractory pediatric inflammatory bowel diseases in the United States

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Tofacitinib is a selective Janus kinase (JAK‐1) inhibitor approved for the treatment of ulcerative colitis (UC) in adults. Data is limited in the pediatric population. The aim of this study was to evaluate the efficacy of tofacitinib in pediatric inflammatory bowel disease (IBD).
Denise D. Young, Jennifer E. Murphy, Mallory Chavannes, Jennifer L. Dotson, Jeanne Tung, Erica Chang, Brad Pasternak, Erin Crawford, Nancy McGreal, Jonathan Moses, Sandra C. Kim   +10 more
wiley   +1 more source

Gastrointestinal strictures in a pediatric patient with Satoyoshi syndrome

JPGN Reports, EarlyView.
Abstract We present a novel case of gastrointestinal strictures in a young girl with Satoyoshi syndrome (SS), highlighting multi‐system features of alopecia universalis, painful muscle cramps with dystonia, aberrant growth velocity, and skeletal abnormalities.
Katherine (Tusia) Pohoreski, Gary Galante, Kiera Pajunen, Marie‐Anne Brundler, Samarjeet Bhandal, Iwona Wrobel   +5 more
wiley   +1 more source

Efficacy of upadacitinib induction for pediatric inflammatory bowel disease

JPGN Reports, EarlyView.
Abstract Objectives Upadacitinib, a second‐generation Janus kinase (JAK) inhibitor, is approved for moderate to severe Crohn's disease (CD) and ulcerative colitis (UC) in adults. Its efficacy in pediatric patients remains unclear, though early reports suggest benefits in refractory inflammatory bowel disease (IBD).
Evan Greenhall, Nina Gautam, Paula Prieto‐Jimenez, Elizabeth Hilow, Ashish Patel, Brad Pasternak   +5 more
wiley   +1 more source

Controlled release of human growth hormone fused with a human hybrid Fc fragment through a nanoporous polymer membrane [PDF]

Nanotechnology has been applied to the development of more effective and compatible drug delivery systems for therapeutic proteins. Human growth hormone (hGH) was fused with a hybrid Fc fragment containing partial Fc domains of human IgD and IgG(4) to ...
Cha, HJ, CHOI, KWAN YONG, Jang, DS, Jin, KS, Kim, ES, Kim, JK, Lee, MN, SUNG, YOUNG CHUL, Yang, SY   +8 more
core   +1 more source

Advancing therapeutic frontiers: a pipeline of novel drugs for UC management

Frontiers in Gastroenterology
Ulcerative colitis is a chronic inflammatory bowel disease with rising global prevalence. Despite therapeutic advances including biologic agents targeting tumor necrosis factor-alpha, integrins, and interleukin pathways, alongside Janus kinase inhibitors
Luisa Bertin, Alessandro Massano, Carlo Redavid, Marco Scarpa, Cesare Ruffolo, Imerio Angriman, Andrea Buda, Fabiana Zingone, Brigida Barberio, Edoardo Vincenzo Savarino   +9 more
doaj   +1 more source

Turmeric and curcumin: From traditional medicine to modern therapeutic applications

JSFA reports, EarlyView.
Abstract Turmeric (Curcuma longa), a medicinal plant, has maintained its cultural and therapeutic significance over centuries in Ayurveda, Unani, and Traditional Chinese Medicine. However, novel formulations and delivery methods are being developed to address these challenges.
Azma Nadeem, Khurram Afzal, Asad Abbas, Talha Bin Iqbal, Abdul Malik, Javaria Saeed, Mutjardah Zarrish, Bipindra Pandey   +7 more
wiley   +1 more source

Association between Polymorphism in the Janus Kinase 2 (JAK2) Gene and Selected Performance Traits in Cattle and Sheep. [PDF]

Animals (Basel), 2023
Oster N, Szewczuk MA, Zych S, Stankiewicz T, Błaszczyk B, Wieczorek-Dąbrowska M.   +5 more
europepmc   +1 more source